Global, regional, and national burden of Hodgkin lymphoma, 1990–2021, and predictions for 2050: an analysis of the global burden of disease study 2021

Despite rising HL cases due to demographic changes, age-standardized incidence, mortality, and DALYs declined substantially over three decades and are projected to continue declining through 2050, indicating improved treatments. Persistent disparities across SDI tiers underscore the need for region-tailored strategies.